On November 26, 2024, Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (CYTK, Financial), sold 7,300 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 111,878 shares of the company.
Cytokinetics Inc (CYTK) is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company's research and development efforts are primarily directed towards advancing its pipeline of drug candidates for the treatment of diseases such as heart failure and amyotrophic lateral sclerosis (ALS).
The insider transaction history for Cytokinetics Inc shows that there have been 0 insider buys in total over the past year. Meanwhile, there have been 53 insider sells over the same timeframe. Over the past year, Fady Malik has sold 190,949 shares in total and purchased 0 shares in total.
Shares of Cytokinetics Inc were trading for $50.16 apiece on the day of Fady Malik’s recent sale. This gives the stock a market cap of $6.139 billion. With a price of $50.16 and a GuruFocus Value of $3.66, Cytokinetics Inc has a price-to-GF-Value ratio of 13.7. This means the stock is significantly overvalued based on its GF Value.
The GF Value is an intrinsic value estimate developed by GuruFocus that is calculated based on the following three factors:
- Historical multiples (price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow) that the stock has traded at.
- A GuruFocus adjustment factor based on the company’s past returns and growth.
- Future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
